gemfibrozil has been researched along with Hypertriglyceridemia in 121 studies
Hypertriglyceridemia: A condition of elevated levels of TRIGLYCERIDES in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These data support the notion that gemfibrozil increases the proportion of polyunsaturated fatty acids in plasma lipids and that this increase is associated with an increase in lipoprotein oxidative susceptibility as measured by lag time in hypertriglyceridemia." | 9.10 | Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia. ( Bibbs, D; Dang, AQ; Faas, FH; Reeves, C; Smith, WG; Wang, J, 2002) |
| "To examine whether lowering of plasma triglyceride concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha agonist gemfibrozil would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 diabetes mellitus." | 9.10 | Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. ( Nattrass, M; Smith, JM; Whitelaw, DC, 2002) |
| "This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity." | 9.09 | Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. ( Avogaro, A; de Kreutzenberg, S; Del Prato, S; Favaro, A; Gottardo, L; Manzato, E; Miola, M; Pacini, G; Piliego, T; Sacerdoti, D; Tiengo, A; Zambon, S, 2001) |
| "Gemfibrozil treatment normalised the defects in chylomicron-like emulsion catabolism observed in endogenous hypertriglyceridemia patients." | 9.09 | The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia. ( Maranhão, RC; Ramires, JA; Santos, RD; Schreiber, R; Spósito, AC; Ventura, LI, 2001) |
| "We evaluated in a double-blind randomized trial with a double-dummy design in 28 patients with primary hypertriglyceridemia, the effect of gemfibrozil (1200 mg/day) versus Omacor (4 g/day), a drug containing the n-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic acid (DHA), on lipid and lipoprotein levels, low density lipoprotein (LDL) subfraction profile and LDL oxidizability." | 9.09 | The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. ( Bredie, SJ; de Graaf, J; Demacker, PN; Kastelein, JJ; Stalenhoef, AF; Wittekoek, ME, 2000) |
| "Thirty middle-aged men selected according to their low density lipoprotein-cholesterol (LDL-C) > or = 160 and < or = 240 mg/dl and borderline hypertriglyceridemia (110-220 mg/dl) after at least one month of a lipid-lowering diet received gemfibrozil (600 mg bid) or simvastatin (20 mg qd) and the corresponding placebo." | 9.09 | Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. ( Cattin, L; Donega, P; Fellin, R; Fonda, M; Gasparrini, S; Marotta, G; Passaro, A; Pauciullo, P; Piliego, T; Vigna, GB; Zanca, R, 1999) |
| "In order to assess the efficacy of gemfibrozil on lipid and haemostatic parameters in patients with plurimetabolic syndrome, a multicenter double-blind placebo controlled, parallel study was carried out in 56 patients with primary hypertriglyceridemia and glucose intolerance." | 9.09 | Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. ( Alessandrini, P; Bittolo Bon, G; Bonfardeci, G; Cimminiello, C; Colombo, L; Mannucci, L; Mussoni, L; Nenci, G; Notarbartolo, A; Parise, P; Pazzucconi, F; Piliego, T; Scafidi, V; Sirtori, C; Tremoli, E, 2000) |
| "We studied the effects of gemfibrozil on glucose and fatty acid metabolism in subjects with mild endogenous hypertriglyceridemia." | 9.08 | Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. ( Knudsen, P; Sane, T; Taskinen, MR; Vuorinen-Markkola, H; Yki-Järvinen, H, 1995) |
| "Gemfibrozil or placebo was administered for 3 months to 24 individuals with endogenous hypertriglyceridemia and normal glucose tolerance." | 9.08 | Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. ( Chen, YD; Fuh, MM; Jeng, CY; Reaven, GM; Sheu, WH; Shieh, SM, 1996) |
| "To examine the effects of gemfibrozil on very-low-density lipoprotein (VLDL) composition and low-density lipoprotein (LDL) size, five men with hypertriglyceridemia (HTG) alone and five men with HTG and hypercholesterolemia (combined hyperlipidemia, CHLP) were randomized for 8 weeks to Lopid SR (slow-release gemfibrozil; two 600-mg tablets once per day) or placebo in a crossover study." | 9.08 | Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. ( Gotto, AM; Gu, ZW; Quion, JA; Valentinova, NV; Xie, YH; Yang, CY; Yang, M; Yeshurun, D, 1996) |
| "To compare the effects of lovastatin and gemfibrozil in patients with primary hyperlipidemias." | 9.07 | [Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias]. ( Batlouni, M; Bertolami, MC; Bismarck, ZF; Faludi, AA; Martinez, TL; Melo, RS; Pinto, LE, 1991) |
| "The effects of gemfibrozil on haemostatic variables were studied in 43 survivors of myocardial infarction with serum triglycerides (TG) greater than or equal to 2 mmol/l 2 weeks prior to randomization." | 9.06 | Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. ( Andersen, P; Arnesen, H; Brataker, S; Seljeflot, I; Smith, P, 1990) |
| "We hereby delineate a rare case of acute pancreatitis secondary to hypertriglyceridemia in a patient who was on tamoxifen treatment for the past 3 years." | 8.31 | Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: A clinical update. ( Abbasi, EUH; Amin, MK; Ashraf, MJ; Goraya, MHN; Hussain, N; Inayat, F; Malik, A; Nawaz, G; Qayyum, M; Zaman, MA, 2023) |
| "Gemfibrozil is a fibrate drug." | 7.77 | [Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia]. ( Ambrosio, G; Chiariello, M; Lepore, S; Napoli, C, 1992) |
| "The aim of this report was to describe a potential drug-drug interaction between IFN alfa-2b and gemfibrozil in a patient with malignant melanoma." | 7.73 | Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma. ( Jakowatz, JG; Taheri, R; Wong, SF, 2005) |
| "Gemfibrozil therapy alone can induce severe myopathy and rhabdomyolysis." | 7.72 | Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglycerdemia while receiving continuous veno-venous hemofiltration therapy. ( Chang, CT; Huang, CC; Wu, MS; Yen, TH, 2003) |
| "The findings in this case indicate that atorvastatin, like other DL-3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, may increase the risk of myositis and rhabdomyolysis when used in combination with gemfibrozil." | 7.70 | Rhabdomyolysis after taking atorvastatin with gemfibrozil. ( Connor, WE; Duell, PB; Illingworth, DR, 1998) |
| "The fibrinolytic and metabolic changes associated with gemfibrozil treatment of hypertriglyceridemia were evaluated in 16 patients with type IV hyperlipidemia by criteria of triglyceride levels > 250 mg/dl and total cholesterol levels < 220 mg/dl." | 7.69 | Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Lee, MM; Sheu, WH; Shieh, SM, 1997) |
| "Gemfibrozil treatment lowered levels of lipid peroxides in both VLDL and HDL particles." | 6.70 | Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia. ( Chen, MF; Hsu, HC; Lee, YT; Yeh, HT, 2001) |
| "Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids." | 6.41 | Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001) |
| "In this case report, the cause of acute pancreatitis was tamoxifen." | 5.33 | Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. ( Alagozlu, H; Cindoruk, M; Unal, S, 2006) |
| "In patients with modest hypertriglyceridemia with lifestyle intervention, APE-H reduced the TG level comparable to the effect of gemfibrozil 300 mg/day." | 5.20 | Effect of Andrographis paniculata Extract on Triglyceride Levels of the Patients with Hypertriglyceridemia: A Randomized Controlled Trial. ( Arkaravichien, T; Aromdee, C; Khampitak, K; Phunikhom, K; Sattayasai, J, 2015) |
| " This study aimed to explore the efficacy and safety of gemfibrozil for hypertriglyceridemia in patients with HIV infection." | 5.10 | A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. ( Amin, J; Brown, D; Carr, A; Cooper, DA; Kaldor, J; Kent-Hughes, J; Law, M; Miller, J, 2002) |
| "To examine whether lowering of plasma triglyceride concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha agonist gemfibrozil would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 diabetes mellitus." | 5.10 | Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. ( Nattrass, M; Smith, JM; Whitelaw, DC, 2002) |
| "This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity." | 5.09 | Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. ( Avogaro, A; de Kreutzenberg, S; Del Prato, S; Favaro, A; Gottardo, L; Manzato, E; Miola, M; Pacini, G; Piliego, T; Sacerdoti, D; Tiengo, A; Zambon, S, 2001) |
| "We evaluated in a double-blind randomized trial with a double-dummy design in 28 patients with primary hypertriglyceridemia, the effect of gemfibrozil (1200 mg/day) versus Omacor (4 g/day), a drug containing the n-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic acid (DHA), on lipid and lipoprotein levels, low density lipoprotein (LDL) subfraction profile and LDL oxidizability." | 5.09 | The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. ( Bredie, SJ; de Graaf, J; Demacker, PN; Kastelein, JJ; Stalenhoef, AF; Wittekoek, ME, 2000) |
| "In order to assess the efficacy of gemfibrozil on lipid and haemostatic parameters in patients with plurimetabolic syndrome, a multicenter double-blind placebo controlled, parallel study was carried out in 56 patients with primary hypertriglyceridemia and glucose intolerance." | 5.09 | Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. ( Alessandrini, P; Bittolo Bon, G; Bonfardeci, G; Cimminiello, C; Colombo, L; Mannucci, L; Mussoni, L; Nenci, G; Notarbartolo, A; Parise, P; Pazzucconi, F; Piliego, T; Scafidi, V; Sirtori, C; Tremoli, E, 2000) |
| "Thirty middle-aged men selected according to their low density lipoprotein-cholesterol (LDL-C) > or = 160 and < or = 240 mg/dl and borderline hypertriglyceridemia (110-220 mg/dl) after at least one month of a lipid-lowering diet received gemfibrozil (600 mg bid) or simvastatin (20 mg qd) and the corresponding placebo." | 5.09 | Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. ( Cattin, L; Donega, P; Fellin, R; Fonda, M; Gasparrini, S; Marotta, G; Passaro, A; Pauciullo, P; Piliego, T; Vigna, GB; Zanca, R, 1999) |
| "Gemfibrozil or placebo was administered for 3 months to 24 individuals with endogenous hypertriglyceridemia and normal glucose tolerance." | 5.08 | Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. ( Chen, YD; Fuh, MM; Jeng, CY; Reaven, GM; Sheu, WH; Shieh, SM, 1996) |
| "We studied the effects of gemfibrozil on glucose and fatty acid metabolism in subjects with mild endogenous hypertriglyceridemia." | 5.08 | Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. ( Knudsen, P; Sane, T; Taskinen, MR; Vuorinen-Markkola, H; Yki-Järvinen, H, 1995) |
| "To examine the effects of gemfibrozil on very-low-density lipoprotein (VLDL) composition and low-density lipoprotein (LDL) size, five men with hypertriglyceridemia (HTG) alone and five men with HTG and hypercholesterolemia (combined hyperlipidemia, CHLP) were randomized for 8 weeks to Lopid SR (slow-release gemfibrozil; two 600-mg tablets once per day) or placebo in a crossover study." | 5.08 | Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia. ( Gotto, AM; Gu, ZW; Quion, JA; Valentinova, NV; Xie, YH; Yang, CY; Yang, M; Yeshurun, D, 1996) |
| "To compare the effects of lovastatin and gemfibrozil in patients with primary hyperlipidemias." | 5.07 | [Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias]. ( Batlouni, M; Bertolami, MC; Bismarck, ZF; Faludi, AA; Martinez, TL; Melo, RS; Pinto, LE, 1991) |
| "The effects of gemfibrozil on haemostatic variables were studied in 43 survivors of myocardial infarction with serum triglycerides (TG) greater than or equal to 2 mmol/l 2 weeks prior to randomization." | 5.06 | Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. ( Andersen, P; Arnesen, H; Brataker, S; Seljeflot, I; Smith, P, 1990) |
| " Efficacy of gemfibrozil was demonstrated in secondary stroke prevention in patients with coronary heart disease and elevated triglyceride levels." | 4.89 | Hypertriglyceridemia as a possible independent risk factor for stroke. ( Basić-Kes, V; Demarin, V; Lisak, M; Trkanjec, Z, 2013) |
| "We hereby delineate a rare case of acute pancreatitis secondary to hypertriglyceridemia in a patient who was on tamoxifen treatment for the past 3 years." | 4.31 | Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: A clinical update. ( Abbasi, EUH; Amin, MK; Ashraf, MJ; Goraya, MHN; Hussain, N; Inayat, F; Malik, A; Nawaz, G; Qayyum, M; Zaman, MA, 2023) |
| "This cross-sectional study was conducted on 90 participants, including 30 individuals with a normal lipid profile (group H), 30 patients with hypertriglyceridemia and not on medication (group N), and 30 patients with hypertriglyceridemia and taking gemfibrozil over a 3-month period (group M)." | 3.85 | Association of Serum Triglyceride Level and Gemfibrozil Consumption With Periodontal Status. ( Akhondi, N; Cheraghi, A; Fallah, S; Moalemnia, AA; Sayar, F, 2017) |
| "Gemfibrozil is a fibrate drug." | 3.77 | [Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia]. ( Ambrosio, G; Chiariello, M; Lepore, S; Napoli, C, 1992) |
| "2%) of participants used 1 of 3 prescription medications indicated to treat hypertriglyceridemia (ie, fenofibrate, gemfibrozil, or niacin); this percentage was 2." | 3.75 | Hypertriglyceridemia and its pharmacologic treatment among US adults. ( Ford, ES; Li, C; Mokdad, AH; Pearson, WS; Zhao, G, 2009) |
| "The aim of this report was to describe a potential drug-drug interaction between IFN alfa-2b and gemfibrozil in a patient with malignant melanoma." | 3.73 | Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma. ( Jakowatz, JG; Taheri, R; Wong, SF, 2005) |
| "After study at entry, in 56 women (median age, 52 years), 36 with familial hypertriglyceridemia, to lower triglycerides, estrogens and SERMs (hormone treatment, HT) were stopped; a very low fat diet (<15% of calories), gemfibrozil (1." | 3.72 | An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. ( Glueck, CJ; Goldenberg, NM; Wang, P, 2003) |
| " Treatment with gemfibrozil, a drug that specifically reduces triglyceride levels, reversed both hypertriglyceridemia and impaired leptin transport." | 3.72 | Triglycerides induce leptin resistance at the blood-brain barrier. ( Banks, WA; Coon, AB; Moinuddin, A; Morley, JE; Nakaoke, R; Robinson, SM; Shultz, JM, 2004) |
| "Gemfibrozil therapy alone can induce severe myopathy and rhabdomyolysis." | 3.72 | Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglycerdemia while receiving continuous veno-venous hemofiltration therapy. ( Chang, CT; Huang, CC; Wu, MS; Yen, TH, 2003) |
| "Hypertriglyceridemia is a well-recognized complication of protease inhibitor therapy, specifically ritonavir." | 3.71 | Sexual dysfunction secondary to gemfibrozil. ( James, CW; McNelis, KC; Wu, TS, 2002) |
| " Eight subjects had hypertriglyceridemia (HTG) and low high-density lipoprotein (HDL), 14 had combined hyperlipidemia (CH), 5 had the apo E2/2 genotype receiving gemfibrozil, 10 were normolipidemic (NL) controls, and 4 had hypercholesterolemia." | 3.71 | Postprandial remnant-like lipoproteins in hypertriglyceridemia. ( Cousins, M; Nakajima, K; Ooi, DS; Ooi, TC; Simo, IE; Steiner, G; Uffelman, KD, 2001) |
| "The findings in this case indicate that atorvastatin, like other DL-3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, may increase the risk of myositis and rhabdomyolysis when used in combination with gemfibrozil." | 3.70 | Rhabdomyolysis after taking atorvastatin with gemfibrozil. ( Connor, WE; Duell, PB; Illingworth, DR, 1998) |
| "Forty kidney-transplanted patients with hypertriglyceridemia, under treatment with cyclosporine alone or associated with other immunosuppressive drugs, were treated with gemfibrozil." | 3.70 | Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients. ( Capone, D; D'Alessandro, R; De Marino, V; Imperatore, P; Pisanti, N; Stanziale, P, 1998) |
| "To compare the short and long term effectiveness of fish oil, insulin, and gemfibrozil in a non-diabetic patient with severe hypertriglyceridemia." | 3.70 | Insulin therapy for a non-diabetic patient with severe hypertriglyceridemia. ( Jabbar, MA; Larrea, J; Zuhri-Yafi, MI, 1998) |
| "The fibrinolytic and metabolic changes associated with gemfibrozil treatment of hypertriglyceridemia were evaluated in 16 patients with type IV hyperlipidemia by criteria of triglyceride levels > 250 mg/dl and total cholesterol levels < 220 mg/dl." | 3.69 | Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Lee, MM; Sheu, WH; Shieh, SM, 1997) |
| " In 55 patients (20 on HD, 13 on CAPD and 22 NDCRF) with severe hypertriglyceridemia or diminished HDL cholesterol gemfibrozil 300 mg b." | 3.68 | Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. ( Dardamanis, MA; Elisaf, MS; Papagalanis, ND; Siamopoulos, KC, 1993) |
| "Atorvastatin was more effective (P < 0." | 2.71 | Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. ( Bonet, R; Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM, 2003) |
| "Gemfibrozil treatment resulted in a decrease in plasma total triglyceride levels and the triglyceride content of all lipoproteins." | 2.70 | Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients. ( Chen, MF; Hsu, HC; Lee, YT; Wang, TD; Yeh, HT, 2001) |
| "Gemfibrozil treatment significantly decreased plasma triglyceride concentration from 316+/-84 to 214+/-82 mg/dl (P < 0." | 2.69 | The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group. ( Avogaro, A; Catapano, A; Miola, M; Piliego, T; Tiengo, A, 1999) |
| "Gemfibrozil was given as 600 mg tablets twice a day for 12 months to a group of middle-aged non-diabetic men with moderate HTG." | 2.68 | Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia. ( Asplund-Carlson, A, 1996) |
| "3." | 2.68 | Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. ( Avogaro, A; Beltramello, P; Biffanti, S; Bonanome, A; Confortin, L; Crepaldi, G; Manzato, E; Marin, R; Tiengo, A; Zambon, S, 1995) |
| "Fifteen normotensive NIDDM patients with hypertriglyceridaemia (> 2." | 2.68 | Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? ( Silberbusch, J; Slaats, EH; Smulders, YM; Stehouwer, CD; van Eeden, AE; Weijers, RN, 1997) |
| "Gemfibrozil is an effective and safe drug in patients with coronary heart disease (CHD) and the high triglyceride-low HDL cholesterol trait." | 2.67 | Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis. ( Kastelein, JJ; Knipscheer, HC; Mulder, WJ; Nurmohamed, MT; Plaat, B; Pruijs, HJ; Van den Ende, A, 1994) |
| "Gemfibrozil (G) is a widely used and highly effective fibric acid derivative." | 2.67 | Activity profile of gemfibrozil on the major plasma lipoprotein parameters. ( Bertoli, M; Calabresi, L; Chiesa, G; Franceschini, G; Gianfranceschi, G; Maderna, P; Sirtori, CR; Vaccarino, V, 1992) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| "Hypertriglyceridemia is commonly embedded in the context of a metabolic syndrome that includes central obesity, insulin resistance, low levels of HDL cholesterol, and often hypertension." | 2.41 | A risk factor for atherosclerosis: triglyceride-rich lipoproteins. ( Kane, JP; Malloy, MJ, 2001) |
| "The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity." | 2.41 | Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001) |
| "Patients with hypertriglyceridemia have been shown to respond well to dietary control and to the use of lipid lowering drugs such as 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG CoA) reductase inhibitors (known as statins), fibrates and nicotinic acids." | 2.41 | Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. ( Breuer, HW, 2001) |
| "Eruptive xanthoma (EX) is a very rare dermatosis mostly occurring due to high levels of serum triglycerides or uncontrolled diabetes mellitus." | 1.42 | First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma. ( Acikgoz, SB; Kara, RO; Kosem, M; Solak, B, 2015) |
| "A case of hypertriglyceridemia-induced acute pancreatitis that was managed with insulin and heparin is reported." | 1.38 | Hypertriglyceridemia-induced acute pancreatitis treated with insulin and heparin. ( Mancell, J; Twilla, JD, 2012) |
| "The conventional methods of treatment of severe hypertriglyceridemia are dietary restriction and lipid lowering medications, mainly fibric acid derivatives." | 1.37 | Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin. ( Pathak, RD; Pathak, SR; Poonuru, S; Vats, HS, 2011) |
| "Obesity is associated with cognitive impairments." | 1.35 | Obesity and hypertriglyceridemia produce cognitive impairment. ( Abdul, HM; Banks, WA; Butterfield, DA; Farr, SA; Miller, NE; Morley, JE; Xu, L; Yamada, KA, 2008) |
| "In this case report, the cause of acute pancreatitis was tamoxifen." | 1.33 | Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. ( Alagozlu, H; Cindoruk, M; Unal, S, 2006) |
| "Monotherapy for the treatment of dyslipidemias is commonly insufficient to achieve all lipid targets recommended by current guidelines." | 1.33 | [Drug combinations: statins and fibrates]. ( Xavier, HT, 2005) |
| "Approximately 80% of patients had elevated cholesterol levels and 60% had elevated low-density lipoprotein levels." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| "Hypertriglyceridemia was found in 6 patients (15%)." | 1.30 | Hypertriglyceridemia during long-term interferon-alpha therapy in a series of hematologic patients. ( Caenazzo, A; Girolami, A; Sartori, R; Scano, F; Sgarabotto, D; Stefani, PM; Vianello, F, 1997) |
| "Hypertriglyceridemia was maintained within acceptable levels, without adjusting the treatment plan, by an appropriate diet and gemfibrosil administration." | 1.28 | Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report. ( Berruti, A; Dogliotti, L; Gorzegno, G; Tampellini, M; Vitetta, G, 1992) |
| "Gemfibrozil was given at a daily oral dose of 600 mg to 28 CAPD patients with serum triglyceride levels higher than 200 mg/dl, after 2 months of low fat low calorie diet." | 1.28 | Gemfibrozil in CAPD patients. ( Castelnovo, C; Colombini, M; De Vecchi, A; Lepore, R; Pini, C; Scalamogna, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.65) | 18.7374 |
| 1990's | 64 (52.89) | 18.2507 |
| 2000's | 39 (32.23) | 29.6817 |
| 2010's | 14 (11.57) | 24.3611 |
| 2020's | 2 (1.65) | 2.80 |
| Authors | Studies |
|---|---|
| Goraya, MHN | 1 |
| Abbasi, EUH | 1 |
| Amin, MK | 1 |
| Inayat, F | 1 |
| Ashraf, MJ | 1 |
| Qayyum, M | 1 |
| Hussain, N | 1 |
| Nawaz, G | 1 |
| Zaman, MA | 1 |
| Malik, A | 1 |
| Sahu, KK | 1 |
| Mishra, AK | 1 |
| Lal, A | 1 |
| Silverman, ES | 1 |
| Kayıkçıoğlu, M | 1 |
| Shahbazova, S | 1 |
| İbrahimov, F | 1 |
| Can, LH | 1 |
| Liu, ZL | 1 |
| Li, GQ | 1 |
| Bensoussan, A | 1 |
| Kiat, H | 1 |
| Chan, K | 1 |
| Liu, JP | 1 |
| Muñoz, MA | 1 |
| Liu, W | 1 |
| Delaney, JA | 1 |
| Brown, E | 1 |
| Mugavero, MJ | 1 |
| Mathews, WC | 1 |
| Napravnik, S | 1 |
| Willig, JH | 1 |
| Eron, JJ | 1 |
| Hunt, PW | 1 |
| Kahn, JO | 1 |
| Saag, MS | 1 |
| Kitahata, MM | 1 |
| Crane, HM | 1 |
| Zborovszky, EC | 1 |
| Santana-Cabrera, L | 1 |
| Ramírez Rodríguez, A | 1 |
| Díaz Mendoza, C | 1 |
| Lisak, M | 1 |
| Demarin, V | 1 |
| Trkanjec, Z | 1 |
| Basić-Kes, V | 1 |
| Raposo, HF | 1 |
| Patrício, PR | 1 |
| Simões, MC | 1 |
| Oliveira, HC | 1 |
| Solak, B | 1 |
| Kara, RO | 1 |
| Acikgoz, SB | 1 |
| Kosem, M | 1 |
| Phunikhom, K | 1 |
| Khampitak, K | 1 |
| Aromdee, C | 1 |
| Arkaravichien, T | 1 |
| Sattayasai, J | 1 |
| Wang, D | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| Béliard-Lasserre, S | 1 |
| Sayar, F | 1 |
| Akhondi, N | 1 |
| Fallah, S | 1 |
| Moalemnia, AA | 1 |
| Cheraghi, A | 1 |
| McBride, P | 1 |
| Ford, ES | 1 |
| Li, C | 1 |
| Zhao, G | 1 |
| Pearson, WS | 1 |
| Mokdad, AH | 1 |
| Yaşar, HY | 1 |
| Ertuğrul, O | 1 |
| Love, BL | 1 |
| Kehr, H | 1 |
| Olin, JL | 1 |
| Cefalù, AB | 1 |
| Noto, D | 1 |
| Arpi, ML | 1 |
| Yin, F | 1 |
| Spina, R | 1 |
| Hilden, H | 1 |
| Barbagallo, CM | 1 |
| Carroccio, A | 1 |
| Tarugi, P | 1 |
| Squatrito, S | 1 |
| Vigneri, R | 1 |
| Taskinen, MR | 3 |
| Péterfy, M | 1 |
| Averna, MR | 1 |
| Poonuru, S | 1 |
| Pathak, SR | 1 |
| Vats, HS | 1 |
| Pathak, RD | 1 |
| Lee, T | 1 |
| Twilla, JD | 1 |
| Mancell, J | 1 |
| Miller, J | 1 |
| Brown, D | 1 |
| Amin, J | 1 |
| Kent-Hughes, J | 1 |
| Law, M | 1 |
| Kaldor, J | 1 |
| Cooper, DA | 1 |
| Carr, A | 1 |
| Yen, TH | 1 |
| Chang, CT | 1 |
| Wu, MS | 1 |
| Huang, CC | 1 |
| Goldenberg, NM | 1 |
| Wang, P | 1 |
| Glueck, CJ | 2 |
| Wagh, A | 1 |
| Stone, NJ | 1 |
| Wägner, AM | 1 |
| Jorba, O | 1 |
| Bonet, R | 1 |
| Ordóñez-Llanos, J | 1 |
| Pérez, A | 1 |
| Banks, WA | 2 |
| Coon, AB | 1 |
| Robinson, SM | 1 |
| Moinuddin, A | 1 |
| Shultz, JM | 1 |
| Nakaoke, R | 1 |
| Morley, JE | 2 |
| Dobordzhginidze, LM | 1 |
| Gratsianskiĭ, NA | 1 |
| Sahhar, NN | 1 |
| Ahmad, AT | 1 |
| Ammari, FL | 1 |
| Ajlouni, KM | 1 |
| Xavier, HT | 1 |
| Wong, SF | 1 |
| Jakowatz, JG | 1 |
| Taheri, R | 1 |
| Fruchart, JC | 1 |
| Duriez, P | 1 |
| Alagozlu, H | 1 |
| Cindoruk, M | 1 |
| Unal, S | 1 |
| Backes, JM | 1 |
| Gibson, CA | 1 |
| Ruisinger, JF | 1 |
| Moriarty, PM | 1 |
| Farr, SA | 1 |
| Yamada, KA | 1 |
| Butterfield, DA | 1 |
| Abdul, HM | 1 |
| Xu, L | 1 |
| Miller, NE | 1 |
| Avellone, G | 1 |
| Di Garbo, V | 1 |
| Cordova, R | 1 |
| Piliego, T | 6 |
| Raneli, G | 1 |
| De Simone, R | 1 |
| Bompiani, GD | 1 |
| Kahri, J | 1 |
| Sane, T | 2 |
| van Tol, A | 1 |
| Knudsen, P | 1 |
| Vuorinen-Markkola, H | 1 |
| Yki-Järvinen, H | 1 |
| Dachet, C | 1 |
| Cavallero, E | 1 |
| Martin, C | 1 |
| Girardot, G | 1 |
| Jacotot, B | 1 |
| Avogaro, A | 3 |
| Beltramello, P | 1 |
| Marin, R | 1 |
| Zambon, S | 2 |
| Bonanome, A | 1 |
| Biffanti, S | 1 |
| Confortin, L | 1 |
| Manzato, E | 2 |
| Crepaldi, G | 1 |
| Tiengo, A | 3 |
| Szostak-Wegierek, D | 1 |
| Nowicka, G | 1 |
| Yuan, J | 1 |
| Tsai, MY | 1 |
| Hunninghake, DB | 1 |
| Cohen, PR | 2 |
| Knipscheer, HC | 1 |
| Nurmohamed, MT | 1 |
| Van den Ende, A | 1 |
| Plaat, B | 1 |
| Pruijs, HJ | 1 |
| Mulder, WJ | 1 |
| Kastelein, JJ | 3 |
| Welborn, TA | 1 |
| Bays, H | 1 |
| Lansing, AM | 1 |
| Simsolo, RB | 1 |
| Ong, JM | 1 |
| Kern, PA | 1 |
| Lang, J | 1 |
| Hamer, T | 1 |
| Tracy, T | 1 |
| Simo, IE | 2 |
| Yakichuk, JA | 1 |
| Ooi, TC | 2 |
| Rubins, HB | 3 |
| Robins, SJ | 2 |
| Iwane, MK | 1 |
| Boden, WE | 1 |
| Elam, MB | 1 |
| Fye, CL | 1 |
| Gordon, DJ | 1 |
| Schaefer, EJ | 1 |
| Schectman, G | 1 |
| Wittes, JT | 1 |
| Elisaf, MS | 1 |
| Dardamanis, MA | 1 |
| Papagalanis, ND | 1 |
| Siamopoulos, KC | 1 |
| Shepherd, J | 1 |
| Jeng, CY | 2 |
| Sheu, WH | 2 |
| Fuh, MM | 1 |
| Shieh, SM | 2 |
| Chen, YD | 1 |
| Reaven, GM | 1 |
| Tikkanen, MJ | 1 |
| Akçiçek, F | 1 |
| Ok, E | 1 |
| Duman, S | 1 |
| Kürsad, S | 1 |
| Unsal, A | 1 |
| Alev, M | 1 |
| Atabay, G | 1 |
| Basçi, A | 1 |
| Yang, CY | 1 |
| Gu, ZW | 1 |
| Xie, YH | 1 |
| Valentinova, NV | 1 |
| Yang, M | 1 |
| Yeshurun, D | 1 |
| Quion, JA | 1 |
| Gotto, AM | 1 |
| Asplund-Carlson, A | 1 |
| Krause, BR | 1 |
| Barnett, BC | 1 |
| Essenburg, AD | 1 |
| Kieft, KA | 1 |
| Auerbach, BJ | 1 |
| Bousley, R | 1 |
| Stanfield, R | 1 |
| Newton, RS | 1 |
| Bisgaier, CL | 1 |
| Bory, E | 1 |
| García Rico, A | 1 |
| Pedro-Botet, J | 1 |
| Sola, R | 1 |
| Orth, M | 1 |
| Luley, C | 2 |
| Sgarabotto, D | 1 |
| Vianello, F | 1 |
| Stefani, PM | 1 |
| Scano, F | 1 |
| Sartori, R | 1 |
| Caenazzo, A | 1 |
| Girolami, A | 1 |
| Pagano, E | 1 |
| Siani, A | 1 |
| Pauciullo, P | 3 |
| Lirato, C | 1 |
| Iacone, R | 1 |
| Sacchi, A | 1 |
| Strazzullo, P | 1 |
| Cimminiello, C | 2 |
| Vigorelli, P | 1 |
| Soncini, M | 1 |
| Toschi, V | 1 |
| Arpaia, G | 1 |
| Perolini, S | 1 |
| Bonfardeci, C | 1 |
| Jeng, JR | 1 |
| Lee, MM | 1 |
| Huang, SH | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Smulders, YM | 1 |
| van Eeden, AE | 1 |
| Stehouwer, CD | 1 |
| Weijers, RN | 1 |
| Slaats, EH | 1 |
| Silberbusch, J | 1 |
| Duell, PB | 1 |
| Connor, WE | 2 |
| Illingworth, DR | 1 |
| Lewis, GF | 1 |
| Uffelman, KD | 2 |
| Lamarche, B | 1 |
| Cabana, VG | 1 |
| Getz, GS | 1 |
| Mukherjee, R | 1 |
| Strasser, J | 1 |
| Jow, L | 1 |
| Hoener, P | 1 |
| Paterniti, JR | 1 |
| Heyman, RA | 1 |
| Vega, GL | 2 |
| Grundy, SM | 3 |
| Stein, JH | 1 |
| Rosenson, RS | 1 |
| Pisanti, N | 1 |
| Stanziale, P | 1 |
| Imperatore, P | 1 |
| D'Alessandro, R | 1 |
| De Marino, V | 2 |
| Capone, D | 1 |
| Lacko, AG | 1 |
| Kudchodkar, BJ | 1 |
| Loney, WW | 1 |
| Clearfield, MB | 1 |
| Weis, S | 1 |
| Jabbar, MA | 1 |
| Zuhri-Yafi, MI | 1 |
| Larrea, J | 1 |
| Weintraub, MS | 1 |
| Charach, G | 1 |
| Grosskopf, I | 1 |
| Hewitt, RG | 1 |
| Shelton, MJ | 1 |
| Esch, LD | 1 |
| Rader, DJ | 1 |
| Haffner, SM | 1 |
| Catapano, A | 1 |
| Miola, M | 2 |
| Minnema, MC | 1 |
| Wittekoek, ME | 2 |
| Schoonenboom, N | 1 |
| Hack, CE | 1 |
| ten Cate, H | 1 |
| Vigna, GB | 1 |
| Donega, P | 1 |
| Passaro, A | 1 |
| Zanca, R | 1 |
| Cattin, L | 1 |
| Fonda, M | 1 |
| Marotta, G | 2 |
| Fellin, R | 1 |
| Gasparrini, S | 1 |
| Mussoni, L | 1 |
| Mannucci, L | 1 |
| Sirtori, C | 1 |
| Pazzucconi, F | 1 |
| Bonfardeci, G | 1 |
| Notarbartolo, A | 1 |
| Scafidi, V | 1 |
| Bittolo Bon, G | 1 |
| Alessandrini, P | 1 |
| Nenci, G | 1 |
| Parise, P | 1 |
| Colombo, L | 1 |
| Tremoli, E | 1 |
| Gaziano, JM | 1 |
| Fornengo, P | 1 |
| Bruno, A | 1 |
| Gambino, R | 1 |
| Cassader, M | 1 |
| Pagano, G | 1 |
| Stalenhoef, AF | 1 |
| de Graaf, J | 1 |
| Bredie, SJ | 1 |
| Demacker, PN | 1 |
| Faergeman, O | 1 |
| Santos, RD | 1 |
| Ventura, LI | 1 |
| Spósito, AC | 1 |
| Schreiber, R | 1 |
| Ramires, JA | 1 |
| Maranhão, RC | 1 |
| Hsu, HC | 2 |
| Lee, YT | 2 |
| Yeh, HT | 2 |
| Chen, MF | 2 |
| Cousins, M | 1 |
| Ooi, DS | 1 |
| Steiner, G | 2 |
| Nakajima, K | 1 |
| Steinmetz, A | 1 |
| Fenselau, S | 1 |
| Schrezenmeir, J | 1 |
| Favaro, A | 1 |
| Gottardo, L | 1 |
| Pacini, G | 1 |
| Sacerdoti, D | 1 |
| de Kreutzenberg, S | 1 |
| Del Prato, S | 1 |
| Westphal, S | 1 |
| Dierkes, J | 1 |
| Breuer, HW | 1 |
| Wang, TD | 1 |
| Silva, RM | 1 |
| Santos, FA | 1 |
| Maciel, MA | 1 |
| Pinto, AC | 1 |
| Rao, VS | 1 |
| Chan, NN | 1 |
| Chow, FC | 1 |
| James, CW | 1 |
| Wu, TS | 1 |
| McNelis, KC | 1 |
| Malloy, MJ | 1 |
| Kane, JP | 1 |
| Whitelaw, DC | 1 |
| Smith, JM | 1 |
| Nattrass, M | 1 |
| Smith, WG | 1 |
| Wang, J | 1 |
| Dang, AQ | 1 |
| Reeves, C | 1 |
| Bibbs, D | 1 |
| Faas, FH | 1 |
| Napoli, C | 1 |
| Lepore, S | 1 |
| Ambrosio, G | 1 |
| Chiariello, M | 1 |
| Ditschuneit, HH | 1 |
| Flechtner-Mors, M | 1 |
| Hagel, E | 1 |
| Ditschuneit, H | 1 |
| Berruti, A | 1 |
| Gorzegno, G | 1 |
| Vitetta, G | 1 |
| Tampellini, M | 1 |
| Dogliotti, L | 1 |
| Sirtori, CR | 1 |
| Franceschini, G | 1 |
| Gianfranceschi, G | 1 |
| Vaccarino, V | 1 |
| Chiesa, G | 1 |
| Maderna, P | 1 |
| Bertoli, M | 1 |
| Calabresi, L | 1 |
| De Vecchi, A | 1 |
| Scalamogna, A | 1 |
| Pini, C | 1 |
| Castelnovo, C | 1 |
| Colombini, M | 1 |
| Lepore, R | 1 |
| Haire, WD | 1 |
| Bertolami, MC | 1 |
| Martinez, TL | 1 |
| Faludi, AA | 1 |
| Pinto, LE | 1 |
| Melo, RS | 1 |
| Bismarck, ZF | 1 |
| Batlouni, M | 1 |
| Magarian, GJ | 1 |
| Lucas, LM | 1 |
| Colley, C | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Andersen, P | 1 |
| Smith, P | 1 |
| Seljeflot, I | 1 |
| Brataker, S | 1 |
| Arnesen, H | 1 |
| Rubba, P | 1 |
| Cortese, C | 1 |
| Caruso, MG | 1 |
| Gnasso, A | 1 |
| Fischetti, A | 1 |
| Motti, C | 1 |
| Mancini, M | 1 |
| Mänttäri, M | 1 |
| Koskinen, P | 1 |
| Manninen, V | 1 |
| Huttunen, JK | 1 |
| Frick, MH | 1 |
| Nikkilä, EA | 1 |
| Rogers, RL | 1 |
| Meyer, JS | 1 |
| McClintic, K | 1 |
| Mortel, KF | 1 |
| Garg, A | 1 |
21 reviews available for gemfibrozil and Hypertriglyceridemia
| Article | Year |
|---|---|
Chinese herbal medicines for hypertriglyceridaemia.
Topics: Drugs, Chinese Herbal; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Randomized C | 2013 |
Hypertriglyceridemia as a possible independent risk factor for stroke.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Gemfibrozil; Humans; Hypertriglyceridemia; Hyp | 2013 |
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
Triglycerides and risk for coronary artery disease.
Topics: Alcohol Drinking; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Hydroxym | 2008 |
[Fibrates: mechanism of action, effect on levels of lipids and lipoproteins, risk of coronary events. Part 1. Clofibrate, gemfibrosil, besafibrate].
Topics: Bezafibrate; Clofibrate; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Li | 2004 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
Fibrates: what have we learned in the past 40 years?
Topics: Clinical Trials as Topic; Clofibric Acid; Coronary Disease; Gemfibrozil; Humans; Hydroxymethylglutar | 2007 |
Dyslipidaemia in non-insulin dependent diabetes: the need for a clinical intervention trial.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Clofibrate; Coronary Disease; Diabetes Mellitus, Type 2; | 1994 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Huma | 1993 |
Selection of appropriate type and intensity of lipid-lowering therapy.
Topics: Cholesterol; Clinical Trials as Topic; Coronary Disease; Diet; Endothelium, Vascular; Enzyme Inhibit | 1995 |
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
Topics: Apolipoproteins B; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hydroxymethylglutaryl-C | 1998 |
Role of fibrates in the management of hypertriglyceridemia.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Gemfibrozil; H | 1999 |
Triglycerides and coronary risk.
Topics: Biomarkers; Coronary Disease; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agent | 1999 |
Hypertriglyceridemia and the fibrate trials.
Topics: Bezafibrate; Cardiovascular Diseases; Clinical Trials as Topic; Female; Gemfibrozil; Humans; Hypertr | 2000 |
Triglycerides and coronary heart disease: implications of recent clinical trials.
Topics: Aged; Bezafibrate; Controlled Clinical Trials as Topic; Coronary Artery Disease; Female; Gemfibrozil | 2000 |
Treatment of dyslipoproteinemia in the metabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; | 2001 |
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hyd | 2001 |
A risk factor for atherosclerosis: triglyceride-rich lipoproteins.
Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym | 2001 |
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; | 1992 |
Gemfibrozil-induced myopathy.
Topics: Clofibrate; Drug Therapy, Combination; Gemfibrozil; Humans; Hypertriglyceridemia; Lovastatin; Male; | 1991 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
45 trials available for gemfibrozil and Hypertriglyceridemia
| Article | Year |
|---|---|
Effect of Andrographis paniculata Extract on Triglyceride Levels of the Patients with Hypertriglyceridemia: A Randomized Controlled Trial.
Topics: Adult; Aged; Andrographis; Animals; Female; Gemfibrozil; Health Behavior; Humans; Hypertriglyceridem | 2015 |
A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia.
Topics: Diet; Double-Blind Method; Female; Gemfibrozil; HIV Infections; HIV Protease Inhibitors; Humans; Hyp | 2002 |
Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; | 2003 |
Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Double-Blind Method; Factor VI | 1995 |
Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Ca(2+) Mg(2+)-ATPase; Carrier Prote | 1995 |
Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia.
Topics: Analysis of Variance; Apolipoprotein A-II; Blood Glucose; Cholesterol; Circadian Rhythm; Double-Blin | 1995 |
Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Gemfibrozil; Humans; Hypertriglyceridemia; Lipoprotein Li | 1995 |
Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Insulin | 1995 |
[Comparative study of the influence of fish oil and gemfibrozil on levels of serum lipoprotein in endogenous hypertriglyceridemia].
Topics: Adult; Aged; Cholesterol, VLDL; Fish Oils; Gemfibrozil; Humans; Hypertriglyceridemia; Lipoproteins; | 1994 |
Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy.
Topics: Adult; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperch | 1994 |
Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol, HDL; Double-Blind Method; Gemfibrozil; Humans; Hypertrig | 1994 |
Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome.
Topics: Adult; Dietary Fats; Double-Blind Method; Eating; Fasting; Gemfibrozil; Humans; Hypertriglyceridemia | 1993 |
Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lip
Topics: Adult; Aged; Cause of Death; Cholesterol, HDL; Cholesterol, LDL; Clinical Protocols; Coronary Diseas | 1993 |
Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Circadian Rhythm; | 1996 |
Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Topics: Adult; Aged; Cholesterol; Combined Modality Therapy; Cross-Over Studies; Diet, Fat-Restricted; Femal | 1996 |
Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia.
Topics: Adult; Apolipoproteins E; Cross-Over Studies; Enzyme-Linked Immunosorbent Assay; Gemfibrozil; Humans | 1996 |
Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia.
Topics: Administration, Oral; Adult; Blood Glucose; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic | 1996 |
Effect of dietary versus pharmacological correction of hypertriglyceridemia on red blood cell membrane sodium/lithium countertransport activity.
Topics: Adult; Biological Transport; Cell Membrane; Diet Therapy; Erythrocytes; Female; Gemfibrozil; Humans; | 1997 |
Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dise | 1997 |
Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy.
Topics: Adult; Aged; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agen | 1998 |
Effects of fibric acid derivatives and metformin on postprandial lipemia.
Topics: Bezafibrate; Chylomicrons; Gemfibrozil; Glucose Tolerance Test; Humans; Hypertriglyceridemia; Hypogl | 1998 |
The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group.
Topics: Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Bl | 1999 |
Activation of the contact system of coagulation does not contribute to the hemostatic imbalance in hypertriglyceridemia.
Topics: Adolescent; Adult; Aged; alpha 1-Antitrypsin; Biomarkers; Blood Coagulation; Blood Proteins; Cholest | 1999 |
Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
Topics: Adult; Aged; Area Under Curve; Blood Coagulation; Cholesterol; Double-Blind Method; Female; Gemfibro | 1999 |
Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.
Topics: Adult; Aged; Blood Glucose; Double-Blind Method; Fatty Acids, Nonesterified; Gemfibrozil; Glucose To | 2000 |
The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
Topics: Adult; Double-Blind Method; Fatty Acids; Fatty Acids, Omega-3; Gemfibrozil; Humans; Hypertriglycerid | 2000 |
The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia.
Topics: Adult; Aged; Apolipoproteins; Case-Control Studies; Cholesterol; Chylomicrons; Computer Simulation; | 2001 |
Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia.
Topics: Adult; Apolipoproteins B; Apolipoproteins C; Apolipoproteins E; Female; Gemfibrozil; Humans; Hypertr | 2001 |
Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients.
Topics: Aged; Arteriosclerosis; Blood Circulation; Diabetes Mellitus, Type 2; Endothelium, Vascular; Gemfibr | 2001 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Adult; Aged; Creatinine; Cross-Over Studies; Cystatin C; Cystatins; Fenofibrate; Gemfibrozil; Homocy | 2001 |
Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients.
Topics: Administration, Oral; Adult; Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypert | 2001 |
Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind | 2002 |
Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia.
Topics: Fatty Acids, Unsaturated; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; L | 2002 |
[Evaluation of the therapeutic efficacy of pravastatin in monothereapy and in association with gemfibrozil in hypercholesterolemia associated with moderate hyperglyceridemia].
Topics: Aged; Drug Evaluation; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; | 1992 |
Postprandial lipoprotein metabolism in obese patients with moderate hypertriglyceridaemia: effects of gemfibrozil.
Topics: Adult; Apolipoproteins; Body Mass Index; Cholesterol; Eating; Fasting; Female; Gemfibrozil; Humans; | 1992 |
Activity profile of gemfibrozil on the major plasma lipoprotein parameters.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Ge | 1992 |
Effect of reduction of plasma triglycerides with gemfibrozil on high-density-lipoprotein-cholesterol concentrations.
Topics: Cholesterol, HDL; Cholesterol, LDL; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Ti | 1992 |
Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients. Double-blind study with gemfibrozil with implications for atherosclerosis.
Topics: Arteriosclerosis; Blood Glucose; Double-Blind Method; Female; Gemfibrozil; Glucose Tolerance Test; H | 1991 |
[Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias].
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholestero | 1991 |
Effects of gemfibrozil on lipids and haemostasis after myocardial infarction.
Topics: Aged; Body Mass Index; Double-Blind Method; Female; Fibrinolysis; Gemfibrozil; Hemostasis; Humans; H | 1990 |
Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyc | 1990 |
Serum lipoproteins, apolipoproteins and very low density lipoprotein subfractions during 6-month fibrate treatment in primary hypertriglyceridaemia.
Topics: Apolipoproteins; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Lipoproteins; Lipoproteins, VLDL | 1990 |
Effect of gemfibrozil on the concentration and composition of serum lipoproteins. A controlled study with special reference to initial triglyceride levels.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Gemfibrozil; Humans; Hypertriglyceridemia; Lipoproteins; | 1990 |
Reducing hypertriglyceridemia in elderly patients with cerebrovascular disease stabilizes or improves cognition and cerebral perfusion.
Topics: Cerebrovascular Circulation; Cerebrovascular Disorders; Cholesterol; Cognition; Female; Gemfibrozil; | 1989 |
Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gemfibrozil; Human | 1989 |
56 other studies available for gemfibrozil and Hypertriglyceridemia
| Article | Year |
|---|---|
Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: A clinical update.
Topics: Acute Disease; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Pancreatitis; Tamoxifen | 2023 |
Update on management of hypertriglyceridaemia-induced acute pancreatitis.
Topics: Abdominal Pain; Adult; Alcohol-Induced Disorders; Female; Fluid Therapy; Gemfibrozil; Humans; Hypert | 2019 |
Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost of Illness; Di | 2020 |
Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.
Topics: Adult; Alabama; Atorvastatin; California; CD4-Positive T-Lymphocytes; Cohort Studies; Comparative Ef | 2013 |
[Plasmapheresis in the treatment of an acute pancreatitis due to hypertriglyceridemia].
Topics: Anti-Bacterial Agents; Critical Care; Enterococcus faecalis; Gemfibrozil; Gram-Positive Bacterial In | 2014 |
Fibrates and fish oil, but not corn oil, up-regulate the expression of the cholesteryl ester transfer protein (CETP) gene.
Topics: Animals; Bezafibrate; Cholesterol Ester Transfer Proteins; Combined Modality Therapy; Corn Oil; Cros | 2014 |
First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Huma | 2015 |
[Fibrates: their prescription must be restricted].
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Prescriptions; Fenofibrate; Fibric Acids; F | 2015 |
Association of Serum Triglyceride Level and Gemfibrozil Consumption With Periodontal Status.
Topics: Adult; Cross-Sectional Studies; Dental Plaque Index; Female; Gemfibrozil; Humans; Hypertriglyceridem | 2017 |
Hypertriglyceridemia and its pharmacologic treatment among US adults.
Topics: Adult; Female; Fenofibrate; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; M | 2009 |
Clomiphene citrate-induced severe hypertriglyceridemia.
Topics: Adult; Cholesterol; Cholesterol, HDL; Clomiphene; Estrogen Antagonists; Female; Gemfibrozil; Humans; | 2009 |
Hypertriglyceridaemia-induced acute pancreatitis due to patient non-compliance.
Topics: Acute Disease; Adult; Analgesics, Opioid; Enoxaparin; Female; Gemfibrozil; Humans; Hypertriglyceride | 2009 |
Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia.
Topics: Adult; Base Sequence; Codon, Nonsense; Gemfibrozil; Genetic Variation; Humans; Hypertriglyceridemia; | 2009 |
Rapid reduction of severely elevated serum triglycerides with insulin infusion, gemfibrozil and niacin.
Topics: Adult; Gemfibrozil; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin | 2011 |
Ask the doctor. On my last blood test, my triglycerides were 280. Should I be worried about that? My doctor wants me to start taking something called Lopid. Is there another solution?
Topics: Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents | 2011 |
Hypertriglyceridemia-induced acute pancreatitis treated with insulin and heparin.
Topics: Acute Disease; Adult; Anticoagulants; Gemfibrozil; Heparin; Humans; Hypertriglyceridemia; Hypoglycem | 2012 |
Acute rhabdomyolysis after gemfibrozil therapy in a pregnant patient complicated with acute pancreatitis and hypertriglycerdemia while receiving continuous veno-venous hemofiltration therapy.
Topics: Acute Disease; Adult; Dose-Response Relationship, Drug; Female; Gemfibrozil; Hemofiltration; Humans; | 2003 |
An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Interactions; Estrogen Replacement Therapy; Fatty Acids | 2003 |
Commentary. Secondary causes of hypertriglyceridemia and pancreatitis.
Topics: Fatty Acids, Omega-3; Female; Gemfibrozil; Hormone Replacement Therapy; Humans; Hypertriglyceridemia | 2003 |
Triglycerides induce leptin resistance at the blood-brain barrier.
Topics: Animals; Biological Transport; Blood-Brain Barrier; Drug Resistance; Fat Emulsions, Intravenous; Gem | 2004 |
Dysregulation of growth hormone in acquired generalized lipodystrophy.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administrati | 2004 |
[Drug combinations: statins and fibrates].
Topics: Age Factors; Clofibric Acid; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Ge | 2005 |
Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Interactions; Gemfibrozil; Humans; Hypert | 2005 |
Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis.
Topics: Acute Disease; Estrogen Antagonists; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemi | 2006 |
Tamoxifen and hypertriglyceridaemia.
Topics: Aged; Breast Neoplasms; Female; France; Gemfibrozil; Humans; Hypertriglyceridemia; Middle Aged; Tamo | 2007 |
Obesity and hypertriglyceridemia produce cognitive impairment.
Topics: Animals; Avoidance Learning; Cognition Disorders; Diet, Atherogenic; Excitatory Postsynaptic Potenti | 2008 |
A therapeutic alternative for managing cyclosporine- and retinoid-induced hypertriglyceridemia.
Topics: Cyclosporine; Gemfibrozil; Humans; Hypertriglyceridemia; Retinoids | 1993 |
Fish oil (omega-3 fatty acids) in treatment of hypertriglyceridemia. A practical approach for the primary care physician.
Topics: Aged; Clofibrate; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Gemfibrozil; Humans; Hype | 1994 |
Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase.
Topics: Adipose Tissue; Adult; Diabetes Mellitus, Type 1; Electrophoresis, Polyacrylamide Gel; Gemfibrozil; | 1993 |
Severe hypertriglyceridemia and pancreatitis when estrogen replacement therapy is given to hypertriglyceridemic women.
Topics: Abdominal Pain; Aged; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Fatty Acids, Omega- | 1994 |
The use of gemfibrozil in a patient with chronic myelogenous leukemia to successfully manage retinoid-induced hypertriglyceridemia.
Topics: Acne Vulgaris; Adult; Combined Modality Therapy; Cytarabine; Gemfibrozil; Humans; Hydroxyurea; Hyper | 1993 |
Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil.
Topics: Adult; Aged; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; H | 1993 |
Opposite effects of bezafibrate and gemfibrozil in both normal and hypertriglyceridemic rats.
Topics: Animals; Apolipoproteins B; Apolipoproteins E; Bezafibrate; Body Weight; Cholesterol; Cholesterol, L | 1996 |
[Severe hypertriglyceridemia during the course of treatment with interferon-alpha in a patient with chronic hepatitis C].
Topics: Adult; Gemfibrozil; Hepatitis C; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Interferon-alph | 1996 |
Diagnostic pitfalls during therapy for extreme hypertriglyceridaemia.
Topics: Adult; Cholesterol, LDL; Combined Modality Therapy; Docosahexaenoic Acids; Eicosapentaenoic Acid; Ge | 1997 |
Hypertriglyceridemia during long-term interferon-alpha therapy in a series of hematologic patients.
Topics: Adult; Aged; Aged, 80 and over; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Interferon-alpha; | 1997 |
Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol.
Topics: Aged; Analysis of Variance; Cholesterol, HDL; Female; Fibrinolysis; Gemfibrozil; Humans; Hypertrigly | 1997 |
Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance.
Topics: Adult; Aged; Cholesterol, HDL; Female; Fibrinolysis; Gemfibrozil; Humans; Hypertriglyceridemia; Hypo | 1997 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
Rhabdomyolysis after taking atorvastatin with gemfibrozil.
Topics: Adult; Atorvastatin; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Heptanoic Ac | 1998 |
Production of small high-density lipoprotein particles after stimulation of in vivo lipolysis in hypertriglyceridemic individuals: studies before and after triglyceride-lowering therapy.
Topics: Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipolysis; Lipoproteins, HD | 1998 |
RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo.
Topics: Acyl-CoA Oxidase; Animals; Bexarotene; Cholesterol, HDL; Drug Combinations; Female; Gemfibrozil; Gen | 1998 |
Treatment of severe hypertriglyceridemia lowers plasma viscosity.
Topics: Adult; Aged; Aged, 80 and over; Blood Viscosity; Cholesterol; Cholesterol, HDL; Female; Fibrinogen; | 1998 |
Lack of effect of gemfibrozil on cyclosporine blood concentrations in kidney-transplanted patients.
Topics: Adult; Cyclosporine; Drug Interactions; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipid | 1998 |
My doctor has me taking Lopid (gemfibrozil) twice a day. My cholesterol level is only 187, but my HDL cholesterol is low at 25. My LDL cholesterol is"normal" at 98 and my triglycerides are 318. These pills give me stomach cramps and they are expensive. Do
Topics: Cholesterol, HDL; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Stomach Diseases | 1998 |
Insulin therapy for a non-diabetic patient with severe hypertriglyceridemia.
Topics: Abdominal Pain; Adolescent; Cholesterol; Fish Oils; Gemfibrozil; Humans; Hypertriglyceridemia; Hypol | 1998 |
Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients.
Topics: Gemfibrozil; HIV Infections; HIV Protease Inhibitors; Humans; Hypertriglyceridemia; Hypolipidemic Ag | 1999 |
Resistant hypertriglyceridemia in a patient with high plasma levels of apolipoprotein CII.
Topics: Adult; Apolipoprotein C-II; Apolipoproteins C; Combined Modality Therapy; Drug Resistance; Fenofibra | 2000 |
Postprandial remnant-like lipoproteins in hypertriglyceridemia.
Topics: Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins; Apolipoproteins B; Cholesterol; Fasting; | 2001 |
Effect of trans-dehydrocrotonin, a 19-nor-clerodane diterpene from Croton cajucara on experimental hypertriglyceridaemia and hypercholesterolaemia induced by Triton WR 1339 (tyloxapol) in mice.
Topics: Animals; Cholesterol; Croton; Diterpenes; Diterpenes, Clerodane; Gemfibrozil; Hypercholesterolemia; | 2001 |
Effects of fenofibrate and gemfibrozil on plasma homocysteine.
Topics: Fenofibrate; Fibrinogen; Gemfibrozil; Homocysteine; Humans; Hypertriglyceridemia; Hypolipidemic Agen | 2001 |
Sexual dysfunction secondary to gemfibrozil.
Topics: Adult; Gemfibrozil; HIV Protease Inhibitors; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Mal | 2002 |
Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Mo | 1992 |
Gemfibrozil in CAPD patients.
Topics: Aged; Cholesterol; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Peritoneal | 1991 |
Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis.
Topics: Cholesterol; Fibrinolysis; Gemfibrozil; Humans; Hypertriglyceridemia; Plasminogen Inactivators; Thro | 1991 |
Treatment choices for hypertriglyceridemia.
Topics: Gemfibrozil; Humans; Hypertriglyceridemia; Lovastatin | 1990 |